论文部分内容阅读
目的报道并分析1例以骨破坏为首发表现的费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL),采用伊马替尼为基础个体化方案的诊断和治疗。方法采用病例报告及文献复习的方式对以骨破坏起病的ALL患者及Ph+ALL治疗进展进行描述。结果患者诊断Ph+ALL明确,经伊马替尼为基础治疗获得诱导缓解,维持分子学缓解17个月。结论对以骨破坏为首发表现者,应考虑ALL诊断可能;伊马替尼为基础的标准化疗方案有可能改善Ph+ALL的治疗模式和预后。
Objective To report and analyze a case of Philadelphia chromosome positive (Ph +) acute lymphoblastic leukemia (ALL) with bone destruction as the first manifestation. The diagnosis and treatment of idiosyncrasy based on imatinib were given. Methods A case report and literature review were conducted to describe the progress of treatment of ALL patients with Phycoerythrotic degeneration and Ph + ALL. Results The diagnosis of patients with Ph + ALL was clear, with imatinib-based treatment of induced remission, to maintain molecular remission for 17 months. Conclusion For the first manifestation of bone destruction, the diagnosis of ALL should be considered. The standard chemotherapy regimen based on imatinib may improve the treatment modality and prognosis of Ph + ALL.